Vardi J, Oberman Z, Rabey I, Streifler M, Ayalon D, Herzberg M
J Neurol Sci. 1976 Nov;30(1):33-40. doi: 10.1016/0022-510x(76)90253-7.
Seven aged Parkinsonian patients treated with levodopa (average dose 3-4 g daily for 1-3 years), showed a considerable weight loss. They were compared to two control groups of elderly and young volunteers after levodopa stimulation and after oral glucose tolerance tests. It was found that after levodopa administration the plasma free fatty acids, glucose, growth hormone and cortisol were significantly higher in the Parkinsonian group than in the young control group and only slightly higher than in the aged control group. It was also found that the serum insulin was significantly higher in Parkinsonian patients than in the aged control group. We think that the metabolic disturbances found in Parkinsonian patients are not solely due to levodopa administration but may be due to ageing processes. We suggest that weight loss in the older Parkinsonian patients treated over long periods with high doses of levodopa, is due to the enhancement of the lipolytic activity of the ageing fat cells caused by high levels of circulating insulin.
七名接受左旋多巴治疗的老年帕金森病患者(平均剂量为每日3 - 4克,治疗1 - 3年)出现了明显的体重减轻。在左旋多巴刺激后以及口服葡萄糖耐量试验后,将他们与老年和青年志愿者的两个对照组进行了比较。结果发现,服用左旋多巴后,帕金森病组的血浆游离脂肪酸、葡萄糖、生长激素和皮质醇显著高于青年对照组,仅略高于老年对照组。还发现帕金森病患者的血清胰岛素显著高于老年对照组。我们认为帕金森病患者中发现的代谢紊乱并非仅由服用左旋多巴所致,可能是由于衰老过程。我们建议,长期大剂量服用左旋多巴治疗的老年帕金森病患者体重减轻,是由于循环胰岛素水平升高导致衰老脂肪细胞的脂解活性增强所致。